Will Kidney Disease Patients Finally Receive New Drug Class? Will Kidney Disease Patients Finally Receive New Drug Class?

Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Source Type: news